Efficacy of TC regimen plus bevacizumab combined with olaparib in the treatment of advanced ovarian cancer and its effect on immune function
ZHANG Can
CHEN Lei
YIN Yi
HE Aiqin
Abstract：Objective To investigate the efficacy of TC regimen(paclitaxel+carboplatin)plus bevacizumab combined with olaparib in the treatment of advanced ovarian cancer and its effect on immune function.Methods A total of 97 patients with ovarian cancer admitted to Nantong Tumor Hospital from June 2020 to June 2023 were selected as the research objects and divided into control group(n=48)and observation group(n=49)by random number table method.The control group was treated with bevacizumab combined with TC regimen,and the observation group was treated with olaparib on the basis of the control group.The clinical efficacy,serum carbohydrate antigen 199(CA199),carbohydrate antigen 125(CA125)and human epididymis protein 4(HE4)levels before treatment and at the end of the 2 nd,4 th and 6 th cycles of treatment,immune function and apoptosis factor levels before and after treatment were compared between the two groups.The adverse reactions during the treatment were observed,and the survival of the two groups was recorded after 1 year of follow-up.Results After treatment,the objective remission rate in the observation group was 69.39%,significantly higher than that in the control group(43.75%),and the difference were statistically significance(P<0.05),whereas no statistically significant difference was found in the disease control rates between the groups(81.63%vs.70.83%,P<0.05).The levels of serum CA199,CA125 and HE4 in the observation group were significantly lower than those in the control group at the end of the 2 nd,4 th and 6 th cycles of treatment(P<0.05).After treatment,the decrease of CD3+,CD4+,CD8+,natural killer(NK)cells,the increase of myeloid-derived suppressor cells(MDSCs),the levels of anti-apoptotic protein Bcl-2 and anti-apoptotic auxiliary protein Bag-1 in the observation group were significantly lower than those in the control group(P<0.05),and the level of pro-apoptotic protein Bax was significantly higher than that in the control group(P<0.05).During the treatment,the incidence of gastrointestinal reaction,hypodynamia,leukopenia and neutropenia in the control group was significantly higher than that in the observation group(P<0.05).The results of Kaplan-Meier survival curve showed that progression-free survival and overall survival in the observation group were significantly higher than those in the control group,and the differences were statistically significant(P<0.05).Conclusion TC regimen plus bevacizumab combined with olaparib in the treatment of ovarian cancer can enhance patients'short-term efficacy,significantly reduce the level of tumor markers,and decrease treatment-related adverse reactions by improving immune status and regulating cytokines,and significantly prolong the patients'survival.
Keywords：ovarian cancerbevacizumabolaparibpaclitaxelcarboplatin
Publication Date：2025-11-28
Online Publishing Date：2026-01-05(First online date of this platform, not the publication date of the document)
Pages：7( 1101-1107 )